Anika Therapeutics Inc.

ANIK Healthcare Drug Manufacturers Specialty & Generic

Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.98 0.71 −3.43%
Market cap
$276.9M
P/E
0.0×
Fwd P/E
−20.0×
Dividend yield
—
F-score
6/9
Altman Z
3.13
Beneish M
−2.84
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 6 6 7
ROE
(20.23%) (7.32%) (7.84%) (2.66%)
ROA
(15.70%) (5.54%) (5.98%) (2.04%)
ROIC
(8.73%) (8.03%) (8.25%) (3.24%)
Return on Tangible Assets
(26.82%) (8.93%) (9.85%) (3.23%)
Average Days of Receivables
71.79 76.64 80.90 87.92
Free Cash Flow per Share
0.09 0.35 (0.21) 0.04
Free Cash Flow
1.25 4.96 (2.86) 0.56
Capital Expenditures
(6.88) (6.23) (9.33) (5.41)
Other line items
Cash ROIC
0.61% 2.47% (1.63%) 0.32%
Accounts Receivable Turnover
4.46 4.77 4.87 4.55
Accounts Payable Turnover
8.85 8.41 8.29 8.29
Inventory Turnover
1.83 2.30 2.18 2.01
Average Days of Payables
33.83 44.99 48.06 49.86
Days of Inventory on Hand
116.42 139.91 173.16 228.39
Tax Rate
0.42 0.07 0.08 0.07
Research and Development Expense of Revenue
22.89% 22.84% 22.73% 22.75%
Selling, General and Administrative Expense of Revenue
42.84% 43.51% 46.41% 43.66%
Share Based Compensation of Revenue
8.76% 8.94% 11.92% 10.90%
Operating CF/Net income
(0.25) (1.03) (0.58) (1.58)
Depreciation/Fixed assets
0.14 0.14 0.14 0.14
Capex/Depreciation
(1.23) (1.09) (1.68) (0.96)
Revenue per Share
7.82 7.87 8.59 9.05
Operating CF per Share
0.56 0.78 0.48 0.45
Capex per Share
(0.48) (0.43) (0.69) (0.41)
Capex to Sales
0.06 0.06 0.08 0.04

Fold the line items

Columns are period end dates